Related Experiment Video
Updated: Aug 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors
P F Smith1, R DiCenzo, G D Morse
1Laboratory for Antiviral Research, University at Buffalo, The State University of New York School of Pharmacy and Pharmaceutical Sciences, Amherst, New York 14260, USA. pfsmith@acsu.buffalo.edu
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) offer a unique approach to HIV-1 treatment by allosterically inhibiting viral reverse transcriptase. Understanding their metabolism and drug interactions is crucial for effective combination antiretroviral therapy.
Area of Science:
- Pharmacology
- Virology
- Medicinal Chemistry
Background:
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral drugs.
- They target the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase enzyme.
- Unlike nucleoside analogues, NNRTIs do not require intracellular phosphorylation for activity.
Purpose of the Study:
- To review the characteristics of approved NNRTIs.
- To highlight their mechanism of action and pharmacokinetic properties.
- To emphasize the clinical significance of drug interactions involving NNRTIs.
Main Methods:
- Review of existing literature on NNRTIs.
- Analysis of molecular and pharmacokinetic profiles of nevirapine, delavirdine, and efavirenz.
- Examination of cytochrome P450 (CYP) enzyme interactions.
Main Results:
- Three NNRTIs (nevirapine, delavirdine, efavirenz) are currently approved.
- NNRTIs induce allosteric changes in HIV-1 reverse transcriptase.
- All NNRTIs are metabolized by the CYP system, leading to potential drug interactions.
Conclusions:
- NNRTIs are effective antiretroviral agents with a distinct mechanism.
- Clinically significant drug interactions due to CYP metabolism are a major consideration.
- Factors like food, pH, and protein binding also influence NNRTI efficacy.
More Related Videos
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antiviral Nucleoside Inhibitors